In partnership with
Don't Buy SpaceX Stock. Buy These 3 Instead.
The biggest IPO in history is live — $1.75T valuation, $135 open, $75B raised. And history says the retail investors who chase day-one hype are the ones who get burned.
The SpaceX run created thousands of new millionaires. But it wasn't the people buying at the open. It was the ones positioned early, in the names set to ride the wave.
Our analyst pinpointed 3 stocks positioned to ride the SpaceX wave — with entry guidance and price targets, a bonus 4th pick (the most undervalued name in the sector), and a 3-phase playbook for when to buy and when to sell.
Over 2,500 investors have already read the report. Claim your free copy here.
Margins and Mix Are Doing the Heavy Lifting
A cautious tape with broader participation is rewarding quality of revenue and stable costs. Healthcare is leading, and software rerates now hinge on whether margin engines can keep turning as growth normalizes.
Today’s market read
The market is cautious, so selectivity is becoming more important.
01 Market Direction
Cautious. Index trends are losing strength, so the market is harder to trust.
02 Market Participation
Broadening. More stocks are joining in.
03 Strongest Sector
Healthcare. Investors are showing the most interest here right now.
F5: Mix and Margins Under the Microscope
Key points
Shares are up 60 percent year to date and about 6 percent below the high.
Third-quarter revenue was 865 million dollars with strong adjusted margins.
Ninety percent of software is subscription and recurring revenue was 594 million dollars.
Fourth-quarter outlook is 870 million to 890 million dollars with margin holding above 83 percent as the gauge.
After a sharp rerating this year and another jump on results, F5's Rally Hinges on Mix and Margins. The quarter brought 11 percent year over year revenue growth to 865 million dollars, with adjusted gross margin at 84.2 percent and adjusted operating margin at 35.0 percent. In a selective tape, those figures kept the quality story intact.
The mix is doing the work. Product revenue outgrew software at 19 percent versus 7 percent, yet margin held because software is largely subscription and security and automation continue to attach. Ninety percent of software is subscription and recurring revenue registered 594 million dollars. Management guided fourth quarter revenue to 870 million to 890 million dollars and pointed to gross margin holding above 83 percent as the near term gauge.
What could break the spell is a slower software trajectory that fails to reaccelerate while systems normalize. A big year to date move compresses room for error, which makes billings, remaining performance obligations, net expansion, and the pace of new automation workloads the next evidence to watch. Competitive pricing and large account spending plans will set the tone for whether margins can keep absorbing mix shifts.
Tenet: A Beat That Rekindles the Facility Trade
Key points
Tenet rallied 17.2 percent on its report, lifting care facility sentiment.
Margin gains came with higher acuity and a better hospital mix despite exchange-plan pressure.
Management raised 2026 revenue, adjusted earnings before interest, taxes, depreciation, and amortization, and cash flow guidance.
The next checks are utilization, payer mix, and labor intensity as peers update in early August.
Healthcare is the market’s strongest sector right now, and Tenet's Beat Rekindles the Facility Trade after a 17.2 percent jump on second quarter results. The move improved sentiment across providers and set up the next round of utilization and pricing checks into August.
Under the hood, Tenet reported about 5.6 billion dollars of net operating revenue and 1.304 billion dollars of consolidated adjusted earnings before interest, taxes, depreciation, and amortization, a 23.2 percent margin for the June quarter. Management raised full year targets for revenue, adjusted earnings before interest, taxes, depreciation, and amortization, and cash flow. Ambulatory care and hospitals both contributed, with same facility net patient revenue up about 5 percent even as cases fell roughly 1 percent. That implies about 6.3 percent revenue per case on higher acuity and a favorable service mix despite pressure tied to exchange plans.
The setup is straightforward. If higher acuity and better reimbursed cases persist while labor intensity stays contained, the rerating can extend. Risks include payer mix shifting the wrong way, staffing costs creeping higher, and utilization normalizing as comparisons tighten. The next catalysts are updates from peers in early August on volumes, acuity, and staffing, which will test whether this margin mix can travel across the group.
On deck this week and next: facility peers update utilization, payer mix, and staffing, while software names face scrutiny on billings, backlog, and pricing power in a more selective tape.